National Cancer Institute of Canada Clinical Trials Group MAR3 trial: Evaluation of exemestane to prevent breast cancer in postmenopausal women

Clinical Breast Cancer

Volumn 7, Issue 11, 2007, Pages 895-900

  Goss, Paul E ^a,h   Richardson, Harriet ^b   Chlebowski, Rowan ^c   Johnston, Dianne ^b   Sarto, Gloria E ^d   Maunsell, Elizabeth ^e   Ingle, James N ^f   Alés Martinez, José E ^g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b QUEEN S UNIVERSITY   (Canada)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e LAVAL UNIVERSITY   (Canada)

^f MAYO CLINIC   (United States)

^g HOSPITAL RUBER INTERNACIONAL   (Spain)

^h MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Aromatase inhibitors; Estrogen receptor; Selective estrogen receptor modulators

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADJUVANT THERAPY; ANOREXIA; ARTHRALGIA; BONE DISEASE; BRAIN ISCHEMIA; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG APPROVAL; DRUG FATALITY; DRUG MECHANISM; ENDOMETRIUM CANCER; FOLLOW UP; FRACTURE; HEART DISEASE; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MORNING DOSAGE; MUSCULOSKELETAL PAIN; MYALGIA; OSTEOPOROSIS; PATHOGENESIS; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM;

EID: 38049037988     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.n.057     Document Type: Article

References (35)

1. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94:606-16.
2. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348:2431-42.
3. NOLVADEX® (tamoxifen citrate tablets). Full prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2006.
4. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97:1652-62.
5. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339:1609-18.
6. Armstrong K, Quistberg DA, Micco E, et al. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med 2006; 166:2260-5.
7. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295:2727-41.
8. EVISTA® (raloxifene hydrochloride). Full prescribing information. Indianapolis, IN: Eli Lilly and Company; 2007.
9. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast caneer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007; 99:272-82.
10. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352:98-101.
11. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998; 352:93-7.
12. Costantino JP, Vogel VG. Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: an alternative view. Clin Breast Cancer 2001; 2:41-6.
13. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361:296-300.
14. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation. Breast Cancer Res Treat 2001; 65:125-34.
15. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96:1751-61.
16. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355:125-37.
17. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295:2742-51.
18. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-2.
19. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353:2747-57.
20. Coombes R, Kilburn L, Snowdon C, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369:559-70.
21. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081-92.
22. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793-802.
23. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J Natl Cancer Inst 2005; 97:1262-71.
24. Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005; 23:6931-40.
25. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol 2005; 23:1636-43.
26. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004. J Clin Oncol 2005; 23:619-29.
27. Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003; 95:526-32.
28. Brewster AM, Christo DK, Lai H, et al. Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits. Cancer 2005; 103:1147-53.
29. Chlebowski RT, Col N, Winer EP, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002; 20:3328-43.
30. Wang X, Chen S. Aromatase destabilizer: novel action of exemestane, a Food and Drug Administration-approved aromatase inhibitor. Cancer Res 2006; 66:10281-6.
31. Miller WR, Dixon JM. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 2001; 79:93-102.
32. Soudon J. Comparison of in vitro exemestane activity versus other antiaromatase agents. Clin Breast Cancer 2000; 1(suppl 1):S68-S73.
33. Miki Y, Suzuki T, Hatori M, et al. Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane. Bone 2007; 40:876-87.
34. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473-83.
35. Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996; 24:161-75.